Skip to main content

Table 2 Patient demographics and overall response to treatment

From: Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn’s Disease

 

AGE years

SEX

CONDITION

DURATION years*

CONCOMITANT THERAPIES

OVERALL RESPONSE TO TREATMENT ^

     NOTES

1

35

F

PD

1.5

Azathioprine 1yr, prednisolone

Cleared

Relapsed on stopping at 12 weeks

2

27

M

PD, MCD

4

Azathioprine 1yr, Prednisolone, Asacol

Two areas healed rest improved prior to exiting

Dropped out due to flare of Crohn’s

3

60

F

PG

33

Azathioprine 2yr, Predfoam, Asacol

Improved

Dropped out - intolerable pain from ointment

4

65

F

PD

10

Nil

Improved

Relapsed on stopping at 12 weeks

5

33

M

GC

12

Nil

Improved initially, worsened during extension

Relapsed on stopping at 12 weeks

6

37

F

GC

5

Prednisolone

Improved

Less frequent and severe swelling.

7

20

M

PD

3

Azathioprine 5yr, Methotrexate

Improved

Dropped out - severe flare of systemic disease

8

12

M

GC

5

Nil

Moderate improvement

Relapsed on stopping at 12 weeks

9

32

M

MCD

4

Azathioprine 2yr

No change

 

10

66

M

PD

1.5

Nil

Initial improvement

Relapsed on stopping at 12 weeks

11

42

M

PD

17

Nil

Improved

 

12

16

M

GC

13

Nil

Mild improvement

Relapsed on stopping at 12 weeks

13

56

F

PD

15

Asacol, Predfoam

Moderate improvement

Relapsed on stopping at 12 weeks

14

29

F

PD

1.5

Nil

No change

 

15

35

M

PD

0.75

Nil

Pronounced improvement

Relapsed on stopping at 12 weeks

16

63

F

PG, PD

6

Nil

Pronounced improvement

Systemic disease flared week 9

17

33

M

PD

5

Nil

Skin healed at 8 weeks but pain continued

Exited trial at week 8

18

15

M

GC

10

Nil

Moderate improvement of lip swelling

Fewer mouth ulcers, relapsed

19

30

M

PD, MCD

25

Nil

Cleared

 

20

38

F

PPG

1.5

Prednisolone, methotrexate, infliximab

Pronounced improvement

Relapsed on stopping at 12 weeks

  1. * Duration of diagnosis of cutaneous Crohn’s disease; ^ Physicians Global Assessment; PD perineal disease; GC granulomatous chelitis; MCD mixed connective tissue disease; PPG peristomal pyoderma gangrenosum.